(Q42986862)

English

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

scientific article published on August 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

S D Sullivan

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

D M Jensen

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

D E Bernstein

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

T I Hassanein

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

G R Foster

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

S S Lee

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

H Cheinquer

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Graham Cooksley

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

W Klaskala

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

K Pettit

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

K K Patel

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

J Green

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

1 August 2004

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

99

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1490-1496

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Epidemiology of hepatitis C in the United States.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Natural history of chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Combination of interferon induction therapy and ribavirin in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Liver transplantation for hepatitis C virus-related cirrhosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Assessment of utilities and health-related quality of life in patients with chronic liver disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Cost effectiveness of combination therapy for hepatitis C: a decision analytic model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30286.X

21 January 2018

Identifiers

10.1111/J.1572-0241.2004.30286.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42986862&oldid=1591354920"